Hainan Huluwa Pharmaceutical Group (605199.SH) announced on July 23 that it has recently received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration for Afutroline tartrate inhalation solution, allowing clinical trials of the drug to proceed. Afutroline tartrate inhalation solution is suitable for the long-term treatment of bronchial constriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
葫芦娃(605199.SH)：酒石酸阿福特罗雾化吸入用溶液获得药物临床试验批准通知书
Hainan Huluwa Pharmaceutical Group (605199.SH): The clinical trial approval notice for Afutelow inhalation solution of tartaric acid has been obtained.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.